US FDA approves Pfizer’s migraine nasal spray Zavzpret
Pharmaceutical Technology
MARCH 10, 2023
The US Food and Drug Administration (FDA) has granted approval for Pfizer ’s Zavzpret (zavegepant) for the acute treatment of migraine in adult patients with or without aura. Zavzpret is claimed to be the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray approved to treat migraine.
Let's personalize your content